CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 185 enrolled
Drug / intervention
Panitumumabbiological
Likely dose
Panitumumab 6 mg/kg intravenous infusion every 2 weeksAI-extracted
Key inclusion· 7
  • ✓Histologically confirmed colorectal adenocarcinoma with metastatic disease
  • ✓Disease progression during or within 6 months after most recent chemotherapy with fluoropyrimidine, irinotecan, and oxaliplatin
  • ✓Radiographically documented disease progression during or within 6 months of most recent chemotherapy
  • ✓Bidimensionally measurable disease
Key exclusion· 5
  • ✕Symptomatic brain metastases requiring treatment
  • ✕History of or current interstitial pneumonitis or pulmonary fibrosis
  • ✕Prior EGFr-targeting agents
  • ✕Chemotherapy or radiotherapy within 30 days before enrollment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00083616
NCT00083616Phase 2Completed
CompareCT.gov

A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

Amgen·interventional·Posted May 28, 2004·Updated Jan 10, 2014

In Brief

A Phase 2 clinical trial evaluating Panitumumab for Colorectal Cancer and Metastatic Cancer. Completed, enrolled 185 participants.

Detailed Summary

The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Metastatic Cancer
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 28, 2004
Enrollment StartMar 1, 2004
Primary CompletionMay 1, 2007
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 22.1 years ago

Interventions

Panitumumabbiological

Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.